Novo Nordisk’s recombinant coagulation factor Ⅷ (turoctocog alfa, trade name: Novoeight) has recently been applied for marketing in China for the treatment of hemophilia A. Chiatai Tianqing previously completed the relevant Phase III clinical trial ahead of Novo Nordisk, however, Novo Nordisk filed the marketing application to the NMPA ahead of Chiatai Tianqing.
